anxiety – Page 5 – mycolab.ai

Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice

mycolabadmin

This study examined how psilocybin works to reduce anxiety in mice by investigating the role of stress hormones, particularly corticosterone. Researchers found that psilocybin causes a temporary spike in corticosterone levels that is essential for its anxiety-reducing effects hours after administration. Interestingly, other interventions that increase corticosterone levels also produced similar anxiety-reducing effects, suggesting the stress hormone response itself drives the therapeutic benefit rather than psilocybin’s psychedelic properties alone. These findings suggest that measuring cortisol levels in human patients receiving psilocybin therapy could help explain and optimize therapeutic outcomes.

The Acute and Chronic Effects of Lion’s Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study

mycolabadmin

This study examined whether Lion’s mane mushroom supplements could improve thinking speed and reduce stress in healthy young adults. Researchers found that a single dose improved how quickly people completed a mental challenge, and four weeks of daily supplements showed a trend toward reducing subjective stress. However, the study was small and found mixed results, including some negative effects on memory tasks, so more research with larger groups is needed to confirm these findings.

4-Hydroxy-N,N-diisopropyltryptammonium hydrofumarate: Crystal Structure of a Synthetic Psychedelic

mycolabadmin

Scientists have determined the three-dimensional crystal structure of 4-HO-DiPT, a synthetic compound related to psilocin found in magic mushrooms. This is the first crystal structure of this specific compound and provides important structural information for understanding how it works. A related version of this compound is currently being tested in clinical trials for treating postpartum depression and other mood disorders.

Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes

mycolabadmin

This study surveyed over 250 million representative American adults about their use of psychedelic mushrooms. Researchers found that about 1.7% of US adults used psychedelic mushrooms in the past year, primarily for general mental health and well-being. Interestingly, those who used them reported higher levels of depression and anxiety, suggesting people with mental health challenges may be self-treating with mushrooms. The findings highlight the need for evidence-based guidelines as more Americans explore psychedelics for health purposes.

A comprehensive overview of the effects of probiotics, prebiotics and synbiotics on the gut-brain axis

mycolabadmin

This comprehensive review examines how probiotics (beneficial live bacteria), prebiotics (food for beneficial bacteria), and synbiotics (combinations of both) can influence communication between the gut and brain. These interventions can produce beneficial compounds like GABA and serotonin, strengthen the gut barrier, and reduce inflammation, potentially helping with mood, anxiety, cognition, and various digestive disorders. However, effects vary greatly depending on the specific strain used, dosage, and individual differences in gut bacteria, and more large-scale studies are needed to confirm long-term clinical benefits.

Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians

mycolabadmin

This review examines the safety of psilocybin therapy for treating anorexia nervosa, a serious eating disorder with limited treatment options. The authors analyze how psilocybin’s common side effects (like increased heart rate, nausea, and dizziness) interact with medical complications already present in people with anorexia. Based on early clinical trials, they conclude that psilocybin can be safely used in this population with proper medical screening and monitoring protocols tailored to their specific vulnerabilities.

Hype or hope? Ketamine for the treatment of depression: results from the application of deep learning to Twitter posts from 2010 to 2023

mycolabadmin

Researchers analyzed over 18,000 Twitter posts from 2010 to 2023 to understand what the public thinks about using ketamine to treat depression. They found that public opinion became much more positive after the FDA approved ketamine as a depression treatment in 2019. Most discussions consisted of personal stories from people who found ketamine helpful, especially those whose depression didn’t respond to other medications. While some people expressed caution and concerns, overall the public seems hopeful about ketamine’s potential.

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

mycolabadmin

This large international study of over 8,700 people found that adults who microdose psychedelics report taking small doses for health and wellness reasons. Among people with anxiety or depression, microdosers showed lower symptom levels than non-microdosers. Most microdosers used psilocybin and combined it with other substances like Lion’s Mane mushrooms or niacin, practices they refer to as stacking.

Harnessing the yeast Saccharomyces cerevisiae for the production of fungal secondary metabolites

mycolabadmin

Scientists have learned to use common baker’s yeast (S. cerevisiae) as a biological factory to produce valuable medicines and compounds that naturally come from fungi and mushrooms. By transferring the genetic instructions for making these compounds into yeast cells and improving them with genetic engineering, researchers can now produce therapeutically important substances like cancer-fighting drugs and antibiotics in large quantities. This approach is more practical and cost-effective than trying to extract these rare compounds directly from their native fungal sources or using other production methods.

The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects

mycolabadmin

This review examines how psilocybin may help treat depression by increasing empathy and prosocial behavior. While psilocybin leaves the body within hours, its antidepressant effects can last months, and researchers believe empathy and helping others may explain this lasting benefit. The authors suggest psilocybin starts a positive cycle where increased empathy leads to helping others, which boosts mood and well-being, which further reinforces empathetic behavior.

Disease: anxiety